Alcon & AMO Development Asked Federal Circuit to Re-Review U.S. Patent No. 8,500,724 Prior to Settlement Pact

AMO Development, LLC, contends a high-energy ablating ultraviolet laser can’t correct internal eye problems because it would first destroy corneal tissue because “laser pulses are highly absorbed in whatever tissue they first encounter.” The U.S. Patent Trial and Appeal Board agreed in IPR2021-00856. Alcon Inc., Alcon Vision, LLC, Alcon Laboratories, Inc., and Alcon Research, LLC, diagree. In cross-appeals, the parties ask the U.S. Court for Appeals for the Federal Circuit to review the PTAB’s inter partes review decision. AMO Development, LLC, the Patent Owner, is represented by a team of lawyers at LATHAM & WATKINS LLP, and Alcon is…